Recent advancements at ASCO 2024 in PD-L1 and PD-1 bispecific antibodies.

IF 2.8 4区医学 Q2 ONCOLOGY

Medical Oncology Pub Date : 2024-11-17 DOI:10.1007/s12032-024-02559-3

Shaza Hammad, Marc Boutros, Fouad Attieh, Hampig Raphaël Kourie

引用次数: 0

Abstract

Recent advancements in cancer immunotherapy have spotlighted the PD-1/PD-L1 pathway, crucial for its role in immune checkpoint regulation. Traditional inhibitors, though successful, face challenges like resistance and adverse effects. Bispecific antibodies targeting PD-1 and PD-L1 present a ground-breaking solution by simultaneously engaging multiple immune regulatory molecules. Developments in PD-1/PD-L1 bispecific antibodies up to now have been summarized, and the latest findings from the 2024 ASCO conference are presented, revealing that bispecific antibodies exhibit robust efficacy in treating various types of cancers, marking a significant step forward in cancer treatment.

查看原文本刊更多论文

2024 年 ASCO 上 PD-L1 和 PD-1 双特异性抗体的最新进展。

癌症免疫疗法的最新进展聚焦于 PD-1/PD-L1 通路，该通路在免疫检查点调节中发挥着至关重要的作用。传统的抑制剂虽然成功，但也面临着耐药性和不良反应等挑战。以 PD-1 和 PD-L1 为靶点的双特异性抗体可同时作用于多种免疫调节分子，是一种突破性的解决方案。本文总结了迄今为止 PD-1/PD-L1 双特异性抗体的发展情况，并介绍了 2024 年 ASCO 会议的最新研究成果，揭示了双特异性抗体在治疗各种癌症方面表现出的强大疗效，标志着癌症治疗向前迈出了重要一步。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Oncology 医学-肿瘤学

CiteScore

4.20

自引率

2.90%

发文量

259

审稿时长

1.4 months

期刊介绍： Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.